WebOne of my mentors is Chureen Carter, PharmD, Vice President of Global Data, Platforms, and Partnerships at Janssen Scientific Affairs. She began her career as a real-world evidence (RWE) fellow, just like me. Carter has worked her way up in the RWE Alliance Strategy and Research Operation environment at Janssen. WebChureen Carter Charles N Ellis Moderate to severe plaque psoriasis (with or without psoriatic arthritis) places significant burden on patients' lives. Explore and document …
distress syndrome among the critically ill: a cohort study
WebJun 7, 2010 · More than half of patients with rheumatoid arthritis who were treated with a biologic discontinued treatment, and another 12% switched to at least 1 other biologic within a 2-year treatment period, according to a study led by Chureen Carter, PharmD, of Centocor Ortho Biotech Services. WebChureen Carter Seina Lee The objective of this study is to compare health outcomes of patients using biologic therapies ustekinumab (UST) or adalimumab (ADA) for moderate-to-severe plaque ... phoneacc8
Mobile health devices diagnose hidden heart condition …
WebAbstract. Objectives: Ustekinumab is the most recently approved biologic for the treatment of moderate-to-severe psoriasis.Real-world dosing patterns of ustekinumab are yet to be fully characterized. Methods: A retrospective, observational study was conducted using MarketScan Commercial and Medicare databases.A cohort of psoriasis patients treated … WebNov 1, 2009 · Europe PMC is an archive of life sciences journal literature. WebChureen T. Carter, Pharm.D., is currently the second year Janssen Pharmaceutica Health Outcomes Research Fellow at Janssen Pharmaceutica in Titusville, New Jersey. She received her doctor of pharmacy degree at Northeastern University in Boston. She is a member of the American Pharmaceutical Association, American Society of Health- phone\\u0027s lidar scanning function